NCT03969004 2025-09-19Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaRegeneron PharmaceuticalsPhase 3 Active not recruiting415 enrolled 1 FDA